Cell Medica, a London, UK-based cellular immunotherapy company focused on the development, manufacturing and marketing of cellular immunotherapy products for the treatment of cancer and infectious diseases, closed a £50m Series B funding round.
The company will use the capital to progress further the development of cellular immunotherapy products.
Led by Gregg Sando, Chief Executive Officer, Cell Medica is advancing its lead oncology product, CMD-003, which is under investigation in the CITADEL Phase 2 clinical trial for the treatment of patients with advanced lymphomas associated with the Epstein Barr virus. Comprised of the patient’s own immune cells, CMD-003 offers the potential for a targeted approach to cancer treatment with very limited side effects or toxicities.
The company is targeting a range of cancer applications associated with the oncogenic Epstein Barr virus including lymphoma, leukaemia and nasopharyngeal carcinoma.